(Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | (Q3)Mar 31, 2022 | (FY)Dec 31, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Turnover | -19.30%2.11B | -18.55%11.51B | -17.25%8.68B | -18.64%5.66B | -22.47%2.62B | -8.86%14.14B | -7.67%10.48B | -7.28%6.96B | 1.01%3.37B | 8.97%15.51B |
Operating income | -19.30%2.11B | -18.55%11.51B | -17.25%8.68B | -18.64%5.66B | -22.47%2.62B | -8.86%14.14B | -7.67%10.48B | -7.28%6.96B | 1.01%3.37B | 8.97%15.51B |
Cost of sales | ---- | 15.34%-4.48B | ---- | 12.15%-2.04B | ---- | 1.09%-5.29B | ---- | ---2.32B | ---- | ---5.35B |
Operating expenses | 21.26%-833.76M | 15.34%-4.48B | 12.82%-3.64B | 12.15%-2.04B | 18.58%-1.06B | 1.09%-5.29B | 0.38%-4.17B | 15.09%-2.32B | -3.84%-1.3B | 2.34%-5.35B |
Gross profit | -17.97%1.28B | -20.48%7.03B | -20.18%5.04B | -21.89%3.62B | -24.90%1.56B | -12.95%8.84B | -11.93%6.31B | -2.80%4.64B | -0.69%2.07B | 16.04%10.16B |
Selling expenses | 21.57%-201.72M | 4.64%-1.48B | -7.65%-1.12B | -1.23%-606.24M | 7.49%-257.18M | 24.63%-1.56B | 24.07%-1.04B | 27.74%-598.85M | 23.67%-277.99M | -21.83%-2.06B |
Administrative expenses | 17.49%-240.92M | 5.33%-1.76B | -7.80%-1.05B | -8.92%-905.79M | 17.44%-291.98M | 25.21%-1.86B | 27.94%-975.73M | 5.72%-831.59M | 8.50%-353.67M | -48.10%-2.49B |
Research and development expenses | 26.41%-3.66M | 57.63%-19.63M | 59.98%-13.77M | 63.30%-9.37M | 63.53%-4.97M | ---46.33M | 18.30%-34.41M | 5.25%-25.52M | -7.43%-13.63M | ---- |
Profit from asset sales | 95.43%-21.31K | ---- | 2,229.29%6.45M | ---- | -104.38%-466.76K | ---- | -102.18%-302.84K | ---- | 5.91%10.65M | ---- |
Revaluation surplus | -2,991.36%-324.39M | -113.00%-1.55B | -557.97%-456.77M | -30.83%-296.25M | -112.50%-10.49M | -194.19%-725.83M | -58.32%99.74M | -199.74%-226.43M | -59.84%83.93M | -149.93%-246.73M |
-Changes in the fair value of investment property | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---246.73M |
-Changes in the fair value of other assets | -2,991.36%-324.39M | -113.00%-1.55B | -557.97%-456.77M | -30.83%-296.25M | -112.50%-10.49M | ---725.83M | -58.32%99.74M | -199.74%-226.43M | -59.84%83.93M | ---- |
Impairment and provision | -53.62%-69.7M | -238.41%-1.3B | -253.57%-741.12M | -48.85%-252.25M | -26.97%-45.37M | 48.83%-385.21M | -22.03%-209.61M | -6.30%-169.47M | -48.08%-35.73M | -63.84%-752.84M |
-Impairment of intangible assets | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---219.59M |
-Other impairment is provision | -53.62%-69.7M | -238.41%-1.3B | -253.57%-741.12M | -48.85%-252.25M | -26.97%-45.37M | 27.76%-385.21M | -22.03%-209.61M | -6.30%-169.47M | -48.08%-35.73M | -16.05%-533.26M |
Special items of operating profit | -228.65%-7.89M | -516.97%-881.04M | -30.45%144.95M | -162.70%-95.02M | -90.87%6.13M | -119.69%-142.8M | -65.04%208.41M | -71.68%151.54M | -50.13%67.2M | 78.53%725.32M |
Operating profit | -60.55%339.89M | -99.10%37.32M | -63.07%1.49B | -50.38%1.46B | -40.90%861.65M | -22.61%4.13B | -14.97%4.05B | -14.70%2.94B | -6.72%1.46B | -1.42%5.33B |
Financing cost | -22.37%-644.51M | -6.04%-2.65B | -6.06%-1.88B | -0.51%-1.26B | 7.71%-526.68M | 7.10%-2.5B | 6.14%-1.77B | -2.63%-1.25B | -0.11%-570.67M | -9.34%-2.69B |
Share of profits of associates | ---- | 6,227.03%65.3M | ---- | 1,217.68%70.19M | ---- | -9.95%1.03M | ---- | --5.33M | ---- | --1.15M |
Share of profit from joint venture company | ---- | 145.18%12.41M | ---- | -40.51%18.57M | ---- | -162.35%-27.47M | ---- | --31.22M | ---- | --44.05M |
Special items of earning before tax | -65.40%-54.4M | ---- | -2,775.61%-165.27M | ---- | -476.94%-32.89M | ---- | 184.23%6.18M | ---- | -174.86%-5.7M | ---- |
Earning before tax | -218.85%-359.02M | -258.96%-2.54B | -124.10%-549.74M | -83.26%288.2M | -65.74%302.08M | -40.48%1.6B | -20.36%2.28B | -22.53%1.72B | -11.89%881.6M | -4.62%2.68B |
Tax | 101.64%1.56M | 96.05%-30.81M | 91.00%-86.12M | 77.07%-174.75M | 61.62%-95.6M | -33.80%-780.77M | -34.23%-956.69M | -31.93%-762.18M | 9.78%-249.12M | 22.20%-583.54M |
After-tax profit from continuing operations | -273.12%-357.45M | -414.66%-2.57B | -148.03%-635.87M | -88.18%113.45M | -67.35%206.47M | -61.11%816.88M | -38.45%1.32B | -41.65%959.75M | -12.69%632.48M | 1.77%2.1B |
Earning after tax | -273.12%-357.45M | -414.66%-2.57B | -148.03%-635.87M | -88.18%113.45M | -67.35%206.47M | -61.11%816.88M | -38.45%1.32B | -41.65%959.75M | -12.69%632.48M | 1.77%2.1B |
Minority profit | -64.19%14.06M | -214.02%-157.71M | -1,359.26%-75.34M | 33.94%-14.75M | 159.95%39.25M | 0.90%138.32M | -93.05%5.98M | -116.50%-22.32M | -3,534.77%-65.47M | -58.90%137.08M |
Profit attributable to shareholders | -322.16%-371.51M | -455.56%-2.41B | -142.53%-560.53M | -86.95%128.2M | -76.04%167.22M | -65.44%678.57M | -36.17%1.32B | -34.95%982.07M | -3.40%697.95M | 13.47%1.96B |
Basic earnings per share | -325.00%-0.09 | -443.75%-0.55 | -143.33%-0.13 | -86.96%0.03 | -75.00%0.04 | -67.35%0.16 | -43.40%0.3 | -41.03%0.23 | -15.79%0.16 | 11.36%0.49 |
Diluted earnings per share | -443.75%-0.55 | -86.96%0.03 | -67.35%0.16 | 0.23 | 0.49 | |||||
Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion |
Auditor | -- | National Health Certified Public Accountants Limited, ZTE Caiguanghua Certified Public Accountants (Special General Partnership) | -- | -- | -- | National Health Certified Public Accountants Limited, ZTE Caiguanghua Certified Public Accountants (Special General Partnership) | -- | -- | -- | National Health Certified Public Accountants Limited, ZTE Caiguanghua Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data